VolitionRX Limited, a clinical-stage life sciences company, focuses on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The company is involved in the development of 28 epigenetic NuQ blood assays based on its Nucleosomics biomarker discovery platform. It develops two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer by detecting nucleosomes containing specific histone variants. The company also develops 17 blood assays in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones that are proteins for packaging and ordering DNA into nucleosomes; 5 blood assays in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts; and a NuQ-T assay to detect cancer by detecting total blood nucleosome levels. In addition, it develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to decide appropriate therapy; NuQ tests for non-cancer conditions; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.
http://www.priceseries.com/trade/VNRX-VolitionRX-Limited-stock-gains-51-percent-a-Trade-Record-by-priceSeries-2017103020171114.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments